The recent approval of Idelalisib, the first oral PI3K inhibitor by the FDA for the treatment of chronic lymphocytic leukemia [23], has triggered the drug industry to search for new PI3K inhibitors that act efficiently and selectively without any side effects. The gene discussed is PIK3CG; the disease is B-cell chronic lymphocytic leukemia.